Calidi Biotherapeutics (CLDI) Accumulated Expenses (2022 - 2026)

Calidi Biotherapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $100000.0 for Q4 2025.

• In Q4 2025, Accumulated Expenses fell 79.17% year-over-year to $100000.0; the TTM figure through Dec 2025 stood at $100000.0 (down 79.17% YoY), while the FY2025 annual figure was $100000.0, down 79.17% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $100000.0, down from $778000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $5.1 million in Q4 2022, with the low at $19000.0 in Q3 2023.
• The 4-year median for Accumulated Expenses is $777282.5 (2022), against an average of $1.8 million.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 97.55% in 2023, then soared 13410.53% in 2024.
• Calidi Biotherapeutics' Accumulated Expenses stood at $5.1 million in 2022, then slipped by 4.78% to $4.9 million in 2023, then slumped by 90.2% to $480000.0 in 2024, then tumbled by 79.17% to $100000.0 in 2025.
• Business Quant data shows CLDI's Accumulated Expenses at $100000.0 in Q4 2025, $778000.0 in Q3 2025, and $1.5 million in Q2 2025.